Prostate Cancer Test - geneType

Get screened based on your personal prostate cancer risk

Current risk assessment for prostate cancer focus on family history.1

However, most men diagnosed with prostate cancer have no significant family history.²

Use geneType for Prostate Cancer to access screening based on your wholistic risk of developing prostate cancer.

Colorectal Cancer

Did you know that four key risk factors contribute to your prostate cancer risk?²

Multi Test risk reduction plan with Doctor

How often should you do a PSA screen? 

PSA screening is an effective tool, but the choice to screen is left up to you and your health provider.¹

Have a more informed discussion with your doctor by knowing your wholistic risk of prostate cancer. 

The geneType patient

GeneType for Prostate Cancer is appropriate for:

  • Men
  • Age 40 – 69 years
  • Non-Hispanic Whites, Non-Hispanic Blacks, Hispanic and Asians 
  • No known hereditary gene mutation e.g.  BRCA2

Uniquely powered to assess your risk

Get a clearer picture of your risk.

Make screening decisions that fit your needs.

Have questions? We have answers.

If your question is not shown here, please contact us directly.

Will insurance cover this test?

No. At this time geneType is a self-pay test. However, you may use FSA/HSA to pay for the test.

Know your risk of prostate cancer
so you can take action

Interested in ordering more than one disease? Order geneType Multi-Test.

See individual disease pages for more information about each test.

The Multi-Risk suite of tests is for adults 40-69 years of age. At maximum, a woman would be eligible for 5 diseases in the panel; a man would be eligible for 4. If patient is younger than 40, they may qualify for geneType's breast or colorectal risk assessments only.

Coming soon: melanoma, pancreatic cancer and atrial fibrillation geneType tests. Patient eligibility dependent on personal medical history, age, sex and self-identified race/ethnicity

What’s happening?

References

1. American Cancer Society Prostate Cancer Screening Recommendations. Accessed June 2022.

2. Rawla P. World J Oncol 2019;10:63–89.

Accredited For Compliance With NPAAC Standards And ISO 15189

CLIA Number 99D2023356